On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

MIDS Cardiac by Zenosense, Inc. (ZENO): A Heart Attack Diagnostic Revolution?

  • The handheld testing device technology under development by Zenosense aims to deliver rapid results and state-of-the-art, laboratory-accurate results for the quick diagnosis of heart attacks
  • Medical professionals believe that diagnosis within 30 minutes of a heart attack is the golden standard for ensuring adequate treatment
  • Cardiac diagnostic testing market estimated between $2 billion and $6 billion in the U.S. alone

MIDS Cardiac™, a handheld diagnostic device for cardiac emergency triage being developed by Zenosense, Inc. (OTCQB: ZENO), could prove to be revolutionary in the diagnostic process. Incorporating the patented MIDS technology, which is predicated on the nano-magnetic detection of assay beads and has demonstrated detection of low enough assay bead numbers to be suitable for high sensitivity cardiac biomarker tests, shows real potential to be able to ensure accurate results, delivered at a fraction of the time required by large and expensive laboratory analyzers and right at the point of care, according to an article by Zacks Small Cap Research (http://ibn.fm/h4VPb) and recent quantitative results released by Zenosense.

The device technology is being created via a partnership between Zenosense and a third-party medical detection device developer. The joint venture carries the name MIDS Medical, and it was set up in the summer of 2016. Zenosense has 40 percent interest in the venture that is based in the UK.

MIDS Cardiac™ is unique, because the technology is being developed to detect very low levels of cardiac markers to deliver accuracy that’s equal or superior to expensive state-of-the-art central laboratory analyzers, all while being accessible at the point of care and offering results within minutes.

The need for such reliable medical technology is growing in the U.S. and throughout the Western world. Anywhere from six to eight million Americans undertake an emergency hospital visit each year due to chest pain and suspected heart attacks. Cardiac diagnostic testing has become incredibly important, and the market niche has grown over the past few years. Currently, the value of the market is estimated between $2 billion and $6 billion in the U.S., as detailed in the Zacks article.

Standard procedure for chest pain patients is an immediate ECG, complemented by blood tests for the cardiac markers troponin I or T, to diagnose AMI. However, the sensitivity of an ECG is recognized as only around 55-75 percent accurate. Troponin proteins are associated with the cardiac muscle and they enter the bloodstream immediately after cardiac arrest. So far, high sensitivity troponin testing requires state-of-the-art laboratory analyzers, which are often unavailable and require at least an hour to turnaround results – a lengthy process that often includes repeated testing to rule out false positives.

Speedy diagnosis is of paramount importance for the treatment of people who have suffered heart attacks. Whenever the flow of blood to the heart is restricted after cardiac arrest, the muscle will begin to deteriorate. The process can be initiated in less than 30 minutes, which is why time is of the essence. Those who receive diagnosis and treatment within the so-called golden hour are more likely to recover without adverse side effects. If treatment does not occur within six hours, most of the heart will be injured beyond repair.

According to the American College of Cardiology and the American Heart Association, myocardial infarction blood tests should ideally be available within 30 minutes. The use of a device like MIDS Cardiac™ could help achieve this goal, as test results are available in a few minutes right at the point of care.

The successful development of MIDS Cardiac™ would be the first step in the development of a wider technology platform that could be adapted to a range of point of care immunoassay tests, based on the same concepts of speed, accuracy, ease of use and cost-effectiveness. Zenosense is planning to use the platform to develop a multi-capability point of care device that would test for different conditions, including prostate, colorectal and other cancers, inflammatory and autoimmune disease, osteoporosis, endocrine ailments, blood infections, respiratory viruses, meningitis, rheumatism, hepatitis, HIV, chlamydia and many more.

For more information, visit the company’s website at www.Zenosense.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered